News Sentiment

QGEN sentiment intelligence

Qiagen NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 62 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 41.51 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+4.5% over one week, +13.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Is Rising Cyclospora Testing Demand Reframing Qiagen’s Infectious Disease Strategy (QGEN)?

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 4.5% Price confirming higher
Trend fit Trend inactive 13.0% over four weeks
Fair value -4.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 34
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
ad-hoc-news.de 9
MarketBeat 7
Investing.com 6
Market source 5
simplywall.st 4
Stock Titan 4
Moomoo 4
TradingView 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 11
Analyst action 11
Macro sensitivity 4
Deals and strategy 4
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
BioSpace Direct company coverage

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN is providing molecular testing solutions to support the public health response to a growing Cyclospora outbreak in the U.S., with over 1,600 confirmed cases since May 2026. Their FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an h

Tone
Positive 72/100
Event
Market update
Published
16 Jul 2026 11:10
Source
BioSpace
Investing.com Direct company coverage

Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak

QIAGEN N.V. announced its molecular testing solutions are available to support the U.S. public health response to a recent cyclosporiasis outbreak, which has over 1,600 confirmed cases. The company's QIAstat-Dx Gastrointestinal Panel 2 can detect the parasite, Cyclospora cayetane

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 00:10
Source
Investing.com
Market source Direct company coverage

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) has announced that it will release its second-quarter 2026 financial results shortly after 16:05 New York time on Wednesday, August 5, 2026. A conference call for investors will follow on Thursday, August 6, 2026, at 09:30

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 22:10
Source
Market source
Stock Titan Direct company coverage

Over 1,600 U.S. Cyclospora Cases; QIAGEN Test Takes an Hour

QIAGEN (QGEN) has highlighted its molecular testing solutions for the growing number of cyclosporiasis cases in the U.S., with over 1,600 confirmed infections since May 2026. The company's FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora in about an hour as p

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 19:41
Source
Stock Titan
Moomoo Direct company coverage

Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns

Berenberg has downgraded Qiagen's rating and reduced its price target, citing increasing competition and decelerating growth potential. This adjustment comes as the analytical instruments and consumables market faces new challenges. Investors will be watching how Qiagen responds

Tone
Negative 29/100
Event
Analyst action
Published
15 Jul 2026 13:41
Source
Moomoo
BioSpace Direct company coverage

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

QIAGEN has launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, significantly expanding its bloodstream infection testing capabilities. This new panel, alongside an existing one, can detect 33 pathogen targets and 28 antimicrobial resistance markers from po

Tone
Positive 74/100
Event
Market update
Published
15 Jul 2026 05:41
Source
BioSpace
TradingView Direct company coverage

Enterprise value to revenue forward of Qiagen N.V. – NYSE:QGEN

This article focuses on the enterprise value to revenue forward metric for Qiagen N.V. (NYSE: QGEN). It appears to be a financial data point presented on TradingView's platform, indicating a specific period and value for this financial ratio. The content itself seems to be a data

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 00:41
Source
TradingView
Investing.com South Africa Direct company coverage

Qiagen launches bloodstream infection test panel in Europe By Investing.com

QIAGEN N.V. (NYSE:QGEN) has launched its CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe for bloodstream infection testing, capable of detecting gram-negative bacterial pathogens and antimicrobial resistance markers. This new panel complements an existing one, colle

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 21:41
Source
Investing.com South Africa
Moomoo Direct company coverage

Berenberg Downgrades QIAGEN to Hold From Buy, Cuts Price Target to $45.50 From $59

Berenberg has downgraded QIAGEN (QGEN) stock from Buy to Hold and significantly cut its price target from $59 to $45.50. This change in rating and price target suggests a more cautious outlook from the investment bank regarding QIAGEN's future performance.

Tone
Negative 28/100
Event
Analyst action
Published
14 Jul 2026 11:41
Source
Moomoo
Investing.com Direct company coverage

Berenberg cuts Qiagen stock rating on competitive pressures

Berenberg has downgraded Qiagen NV to Hold from Buy and reduced its price target due to competitive pressures on its QuantiFERON franchise and weakening expectations for U.S. life sciences research spending. Despite a new buyback program and the stock appearing slightly undervalu

Tone
Negative 34/100
Event
Analyst action
Published
14 Jul 2026 08:52
Source
Investing.com
Investing.com Direct company coverage

Berenberg downgrades Qiagen stock rating on competitive concerns

Berenberg downgraded Qiagen NV's stock rating from Buy to Hold and lowered its price target due to concerns about the deterioration of its outlook in the first half of 2026 and increasing competitive pressure for its QuantiFERON franchise. The firm cited lower immigration demand

Tone
Negative 31/100
Event
Analyst action
Published
14 Jul 2026 08:52
Source
Investing.com
marketscreener.com Direct company coverage

QIAGEN NV : Reduced to Neutral by Berenberg

Berenberg has downgraded its recommendation for QIAGEN NV to Neutral, lowering the target price from EUR 50 to EUR 40. This revision comes amidst recent news regarding potential takeover interest in Qiagen from private equity firms like EQT, Advent, and KKR. The article also list

Tone
Negative 33/100
Event
Analyst action
Published
14 Jul 2026 08:40
Source
marketscreener.com
StreetInsider Direct company coverage

Berenberg Downgrades Qiagen NV (QGEN) to Hold

Berenberg analyst Harry Gillis downgraded Qiagen NV (QGEN) from Buy to Hold. The price target for QGEN was also adjusted to $45.50. This change in rating reflects a revised outlook from the analyst for the company.

Tone
Negative 29/100
Event
Analyst action
Published
14 Jul 2026 07:40
Source
StreetInsider
DirectorsTalk Interviews Direct company coverage

Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator With A Promising 7.11% Upside

Qiagen N.V. (QGEN) is highlighted as a prominent healthcare innovator in diagnostics and research, with analysts projecting a 7.11% upside. Despite a recent modest stock decrease, the company's strong product offerings, healthy free cash flow, and positive analyst sentiment make

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 10:19
Source
DirectorsTalk Interviews
MarketBeat Direct company coverage

Qiagen N.V. (NYSE:QGEN) Given Consensus Rating of "Hold" by Analysts

Analysts have given Qiagen N.V. (NYSE:QGEN) a consensus "Hold" rating based on reports from thirteen research firms, with an average 12-month price target of approximately $43.15. The company recently reported quarterly earnings of $0.54 per share, meeting expectations, and incre

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 08:26
Source
MarketBeat
MarketBeat Direct company coverage

Arbejdsmarkedets Tillaegspension Raises Holdings in Qiagen N.V. $QGEN

Arbejdsmarkedets Tillaegspension increased its stake in Qiagen N.V. by 24.8% in the first quarter, bringing its total holdings to 636,918 shares valued at approximately $25.5 million. Other institutional investors also raised or initiated positions, with hedge funds now owning ab

Tone
Positive 64/100
Event
Earnings
Published
13 Jul 2026 08:10
Source
MarketBeat
Kavout | AI Direct company coverage

Qiagen's Automation Pipeline: A Hidden Catalyst for a 2027 Rebound

Despite a recent revenue miss and a cut to its 2026 financial outlook due to near-term challenges, Qiagen is aggressively pursuing a multi-pronged automation strategy with new sample preparation instruments and an expanded digital PCR portfolio slated for 2025-2026 launches. Thes

Tone
Positive 70/100
Event
Earnings
Published
12 Jul 2026 21:10
Source
Kavout | AI